Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine vs ECT for Suicidal Ideation in Depressive Episodes
NCT06355180Completed
- Sponsor
- Capital Medical University
- Start
- Apr 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of esketamine in suicidal ideation (2 arms), sponsored by Capital Medical University. Primary endpoint: Remission rate of suicidal ideation at 2 weeks. Started Apr 2024; status: completed.
02
Drugs
esketamine
03
Conditions
suicidal ideation
Beyond the preview
Go deeper on NCT06355180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06355180.